Patents Examined by Heidi Reese
  • Patent number: 11504372
    Abstract: The subject matter generally relates to methods of treatment and/or prophylaxis of CNS diseases, disorders, and/or injuries. In one aspect, the subject matter relates to inhibitors of phosphodiesterase 1 (PDE1) as neuroprotective agents and/or neural regenerative agents. In a further aspect, the subject matter relates to individuals that are at risk for the development of CNS disease or disorder.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: November 22, 2022
    Inventor: Lawrence P. Wennogle
  • Patent number: 11484525
    Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: November 1, 2022
    Assignees: The Regents of the University of California, Friedrich-Alexander-Universität Erlangen-Nürnberg, The Board of Trustees of the Leland Stanford Junior University, The University of North Carolina at Chapel Hill
    Inventors: Brian K. Shoichet, Henry Lin, Peter Gmeiner, Aashish Manglik, Brian Kobilka, Bryan L. Roth, Daniela Gisela Dengler
  • Patent number: 11478478
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 25, 2022
    Inventors: Dominique Amans, Stephen John Atkinson, Lee Andrew Harrison, David Jonathan Hirst, Robert Peter Law, Matthew Lindon, Alexander Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • Patent number: 11478466
    Abstract: Provided are compositions and methods for promoting osteogenic differentiation of undifferentiated cells, such as stem cells. An example of a compound useful in the present method is 6,8-dimethyl-3-(4-phenyl-1H-imidazol-5-yl)quinolin-2(1H)-one (DIPQUO). The present methods can be used for treatment and prevention of bone disorders.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: October 25, 2022
    Assignee: Cornell University
    Inventors: Todd Evans, Brandoch Cook, Shuibing Chen
  • Patent number: 11464810
    Abstract: A method of preventing or treating eosinophilic esophagitis (EoE) comprising administering a composition comprising ascr#7 is described.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: October 11, 2022
    Assignees: California Institute of Technology, Boyce Thompson Institute for Plant Research
    Inventors: Andrea Choe, Paul W. Sternberg, Frank C. Schroeder
  • Patent number: 11465985
    Abstract: The disclosure provides processes for preparing a compound of Formula (I).
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 11, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul T. Angell, Cristian Harrison, Robert M. Hughes, Berenice Lewandowski, Benjamin J. Littler, Vito Melillo, William A. Nugent, David Andrew Siesel, David Smith, John Studley
  • Patent number: 11465981
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: October 11, 2022
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Zhiyong Yu, Fenglei Zhang, Wenqing Yao
  • Patent number: 11459315
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compostions thereof, which are useful for treating a variety of conditions associated with methyl modifying enzymes.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 4, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Jehrod B. Brenneman, Alexandre Côté, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Ludivine Moine
  • Patent number: 11459324
    Abstract: Described herein are compounds represented by formula (I?) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, Ra, Rb, m, n, Y1, Y2, R3 and R4 are defined herein.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 4, 2022
    Assignee: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Patent number: 11459321
    Abstract: Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-spectrum viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: October 4, 2022
    Assignee: Evrys Bio, LLC
    Inventors: Stacy Remiszewski, Lillian W. Chiang, Eain Anthony Murphy, Qun Sun, Frank Kayser, Sarah Jocelyn Fink
  • Patent number: 11459339
    Abstract: Disclosed are a biaryl derivative having a structure represented by Formula (I) and inhibitory activity against PD-1/PD-L1 interaction, a preparation method thereof, and a pharmaceutical application thereof. The series of compounds of the can be widely applied to the preparation of a medicament for preventing and/or treating cancer or tumors, immune-related diseases and disorders, contagious diseases, infectious diseases or metabolic diseases that are mediated by a PD-1/PD-L1 signaling pathway, and shows promise for the development of a new generation of PD-1/PD-L1 inhibitors.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: October 4, 2022
    Inventors: Fei Yang, Yongxian Zhang, Haiyan Ying, Hongping Yu, Zhui Chen, Yaochang Xu
  • Patent number: 11459331
    Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as prostaglandin EP4 receptor antagonists, and are useful in the treatment or alleviation of pain and inflammation and other inflammation-associated disorders, such as arthritis, treating or preventing disorders or medical conditions selected from pain, inflammatory diseases and the like. Also described herein are methods of treating pain by administering the compounds of the disclosure, which are EP4 receptor antagonists.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: October 4, 2022
    Assignee: Avista Pharma Solutions, Inc.
    Inventors: Jason D. Speake, Brent Christopher Beck, Bharathi Pandi, Jennifer C. Freeman
  • Patent number: 11453674
    Abstract: Provided are a heterocyclic compound, a preparation method and the use thereof in medicine, and particularly involved are a heterocyclic compound for preventing and/or treating hypemricemia and gout, a preparation method and the use thereof in medicine. In particular, provided are a compound as shown in formula (I) and/or formula (II) or a tautomer thereof and a pharmaceutically acceptable salt thereof, a preparation method therefor and a method and the use thereof for treating hypemricemia and gout.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: September 27, 2022
    Inventors: Yuchuan Wu, Xi Chen, Shaoqiang Huang, Yonghan Hu, Linhai Qu, Jinlian Zhu, Xiao Liu
  • Patent number: 11447484
    Abstract: Novel compounds having a D3 receptor antagonistic activity are provided. The compound represented by Formula (I): wherein Ring A is a non-aromatic heterocycle or the like substituted with substituted or unsubstituted aromatic heterocyclyl or the like; R2a to R2d are each independently a hydrogen atom or the like; n is an integer of 0 to 3; Ring B is a non-aromatic carbocycle or the like; R3 is each independently halogen or the like; r is an integer of 0 to 4; -L- is —N(R10)—C(?O), or the like; R10 is a hydrogen atom or the like; R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 20, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yusuke Ichihashi, Masanao Inagaki, Koji Masuda
  • Patent number: 11446287
    Abstract: Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: September 20, 2022
    Assignee: Opna Immuno-Oncology SA
    Inventors: Wayne Spevak, John Buell, Zuojun Guo, Hiroaki Inagaki, Yongil Jin, Phuongly Pham, Songyuan Shi, Jack Walleshauser, Jeffrey Wu, Guoxian Wu, Chao Zhang, Jiazhong Zhang, Ying Zhang
  • Patent number: 11440898
    Abstract: The application is directed to compounds of formula (I):(I), and formula (IA):(IA) and their salts and solvates, wherein R1, R2, R3, R4, R5, n, A1, A2, A3, and Y are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of ?-galactosidase, specially galactosidase beta-1 or GLB 1, including GM 1 gangliosidoses and Morquio syndrome, type B.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: September 13, 2022
    Assignee: Minoryx Therapeutics S.L.
    Inventors: Ana Maria García Collazo, Marc Martinell Pedemonte, Elena Cubero Jordà, Xavier Barril Alonso, Laura Pilar Rodriguez Pascau
  • Patent number: 11439635
    Abstract: Disclosed are methods and compositions for treating diabetes mellitus and non-alcoholic fatty liver disease by administering a therapeutic agent that inhibits the biological activity of B cell lymphoma 6 protein (BCL6).
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: September 13, 2022
    Inventors: Grant D. Barish, Meredith A. Sommars, Madhavi D. Senagolage
  • Patent number: 11440883
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: September 13, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Patent number: 11433061
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 6, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M. K. Pennell, John J. Wright, Antoni Krasinski, Qiang Wang
  • Patent number: 11433048
    Abstract: The invention relates to a CXCR4 receptor-binding compound for use for increasing or restoring interferon (IFN) level in an individual, wherein the interferon is a type-I interferon (IFN-I).
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 6, 2022
    Inventors: Nicolas Pietrancosta, Nikaïa Smith, Jean-Philippe Herbeuval